FDA, Friends identify next steps for dose optimization, pragmatic trials, academic-led studies for drug approvals December 15, 2023Vol.49 No.46By Matthew Bin Han Ong
Guest Editorial “Do no harm” must guide social media for healthcare professionals December 15, 2023Vol.49 No.46By Samir N. Khleif, Raphael E. Pollock and Robert A. Winn
FreeObituary Cullen Taniguchi, radiation oncologist at MD Anderson, dies at 47 December 15, 2023Vol.49 No.46By Albert C. Koong
EditorialFree Top 25 stories of 2023 December 15, 2023Vol.49 No.46By Alexandria Carolan and Katie Goldberg
Cancer History ProjectFree The Cancer History Project’s top 25 stories of 2023 December 15, 2023Vol.49 No.46By Alexandria Carolan and Katie Goldberg
Free After more than a decade, ASCO sells CancerLinQ to ConcertAI December 11, 2023Vol.49 No.46By Paul Goldberg
Conversation with The Cancer LetterFree Hudis: ASCO had the vision, but was low on resources CancerLinQ required December 11, 2023Vol.49 No.46By Paul Goldberg
News Analysis Dana-Farber’s bold split from the Brigham is a culmination of Boston oncology’s complicated history December 08, 2023Vol.49 No.45By Jacquelyn Cobb
As Bertagnolli steps in, NIH and FDA reenvision clinical trials and evidence generation December 08, 2023Vol.49 No.45By Matthew Bin Han Ong
Guest Editorial New leadership, vision for the Worldwide Innovative Network Consortium in precision oncology December 08, 2023Vol.49 No.45By Wafik S. El-Deiry
